Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]
Lire la suiteContaminants of Concern in Cannabis : Microbes, Heavy Metals and Pesticides John M. McPartland and Kevin J. McKernan in S. Chandra et al. (eds.), Cannabis sativa L. - Botany and Biotechnology, Chapter 22, 2017, 457-474. Doi : 10.1007/978-3-319-54564-6_22 Abstract Microbiological contaminants pose a potential threat to cannabis consumers. Bacteria and fungi may cause opportunistic infections in immuno-compromized individuals. Even dead organisms may trigger allergies and asthma. Toxins from microbial overloads, such as Shigla toxin and aflatoxins, may pose a problem—unlikely, but possible. The Cannabis plant hosts a robust microbiome; the identification of these organisms is underway. Cannabis bioaccumulates heavy metals in its tissues, so avidly [...]
Lire la suiteThe Genetic Structure of Marijuana and Hemp Jason Sawler, Jake M. Stout, Kyle M. Gardner, Darryl Hudson, John Vidmar, Laura Butler, Jonathan E. Page, Sean Myles PLoS ONE, 2015, 10, (8), e0133292. doi : 10.1371/journal.pone.0133292 Abstract Despite its cultivation as a source of food, fibre and medicine, and its global status as the most used illicit drug, the genus Cannabis has an inconclusive taxonomic organization and evolutionary history. Drug types of Cannabis (marijuana), which contain high amounts of the psychoactive cannabinoid Δ9-tetrahydrocannabinol (THC), are used for medical purposes and as a recreational drug. Hemp types are grown for the production of seed and fibre, and contain [...]
Lire la suiteData Supporting Cannabis for Childhood Epilepsy Remain Scarce Will Pass Medscape.com, September 13, 2021 https://www.medscape.com/viewarticle/958616 Cannabis-based medicinal products (CBMPs) have shown early promise for refractory childhood epilepsy, but positive media attention, as well as pressure from politicians and marijuana advocacy groups, should not supplant clinical trials and acceptable standards of evidence, according to two leading experts. In a recent invited review article, Martin Kirkpatrick, MD, of the University of Dundee (Scotland), and Finbar O'Callaghan, MD, PhD, of University College London suggested that childhood epilepsy may be easy terrain for commercial interests to break ground, and from there, build their presence. "Children with epilepsy are at risk of being [...]
Lire la suiteAn Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom Jonathan Paul Liebling, Nicholas James Clarkson, Blair William Gibbs, Andrew Stephen Yates, and Saoirse Elizabeth O’Sullivan Cannabis and Cannabinoid Research, 2020, 1-7. DOI: 10.1089/can.2019.0078 Abstract Introduction : Over-the-counter cannabidiol (CBD) products have seen unprecedented recent growth in the United Kingdom. However, analysis of these predominantly unregulated products from other countries tells us that they are often mislabeled or contain unlabeled and potentially dangerous chemicals. Thus, the aim of the present study was to analyze CBD oils available in the United Kingdom. Materials and Methods: Phytocannabinoids, residual solvent, and heavy metals were measured blinded in 29 [...]
Lire la suiteCannabis : From Cultivar to Chemovar II—A Metabolomics. Approach to Cannabis Classification Arno Hazekamp, Katerina Tejkalova, and Stelios Papadimitriou Cannabis and Cannabinoid Research, 2016, Volume 1, (1) Doi : 10.1089/can.2016.0017 Abstract Introduction : There is a large disparity between the ‘‘cultural’’ language used by patients using cannabis for selfmedication and the ‘‘chemical’’ language applied by scientists to get a deeper understanding of cannabis effects in laboratory and clinical studies. The distinction between Sativa and Indica types of cannabis, and the different biological effects associated with them, is a major example of this. Despite the widespread use of cannabis by selfmedicating patients, scientific studies are yet [...]
Lire la suiteDo medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers? Sharon R. Sznitman, Monica J. Barratt, Tom Decorte, Pekka Hakkarainen, Simon Lenton, Gary Potter, Bernd Werse and Chris Wilkins Drugs and Alcohol Today, 2019, 19, (4), 251-256, Doi : 10.1108/DAT-06-2019-0021 Abstract Purpose – It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the therapeutic index of their cannabis by attempting to produce particular concentrations of CBD and/or THC. The purpose of this paper is to examine whether small-scalemedical cannabis growers differ fromthose growing for recreational reasons in terms of self-assessed concentrations of THC and CBD [...]
Lire la suiteDeveloping Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry Matthew T. Welling, Lei Liu, Arno Hazekamp, Ashley Dowell, Graham J. King Medical Cannabis & Cannabinoids, 2019, 2, 1–13 Doi : 10.1159/000496868 Abstract The plant genus Cannabis is a prolific producer of unique pharmaceutically relevant metabolites, commonly referred to as cannabinoids. Robust and standardised methods for the quantification of cannabinoids within botanical and drug forms is a critical step forward for an emerging Cannabis- based pharmaceutical industry, which is poised for rapid expansion. Despite a growing body of analytical methods for the quantification of cannabinoids, few have [...]
Lire la suiteL’huile de chanvre contient-elle du THC et du CBD ? Newsweed, 11 février 2020 Aurélien BERNARD https://www.newsweed.fr/huile-chanvre-contient-thc-cbd/ L’huile de chanvre, extraite des graines, est une source précieuse d’omega 3 et 6 et de nutriments dans l’alimentation quotidienne. Sa valeur nutritionnelle et thérapeutique pourrait néanmoins aussi être attribuée à sa composition en cannabinoïdes qui, si faiblement présents, existent quand même. Dans une étude de 2019, plusieurs cannabinoïdes ont été détectés dans l’huile de graines de chanvre et permettent de déterminer des différences dans leur composition chimique. Bien que le CBDA et le CBD soient prédominants dans les dix huiles étudiées, 20 autres cannabinoïdes «mineurs» ont été [...]
Lire la suiteComprehensive classification of USA cannabis samples based on chemical profiles of major cannabinoids and terpenoids Ramia Z. Al Bakain, Yahya S. Al-Degs, James V. Cizdziel and Mahmoud A. Elsohly Journal of Liquid Chromatography & Related Technologies, 2019 Doi : 10.1080/10826076.2019.1701015 ABSTRACT Different USA-origin cannabis samples were analyzed by GC-FID to quantify all possible cannabinoids and terpenoids prior to their clustering. Chromatographic analysis confirmed the presence of seven cannabinoids and sixteen terpenoids with variable levels. Among tested cannabinoids, D9-Tetrahydro-cannabinol D9-THC and cannabinol CBN were available in excess amounts (1.2–8.0 wt%) and (0.22–1.1 wt%), respectively. Fenchol was the most abundant terpenoid with a range of (0.03–1.0 wt%). [...]
Lire la suite